Charles Haworth

14.1k total citations · 7 hit papers
134 papers, 5.0k citations indexed

About

Charles Haworth is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Emergency Medical Services. According to data from OpenAlex, Charles Haworth has authored 134 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Pulmonary and Respiratory Medicine, 39 papers in Epidemiology and 23 papers in Emergency Medical Services. Recurrent topics in Charles Haworth's work include Cystic Fibrosis Research Advances (89 papers), Tracheal and airway disorders (25 papers) and Neonatal Respiratory Health Research (24 papers). Charles Haworth is often cited by papers focused on Cystic Fibrosis Research Advances (89 papers), Tracheal and airway disorders (25 papers) and Neonatal Respiratory Health Research (24 papers). Charles Haworth collaborates with scholars based in United Kingdom, Italy and United States. Charles Haworth's co-authors include Diana Bilton, R. Andrés Floto, J. Foweraker, Michael R. Loebinger, James D. Chalmers, Amanda Adler, Charles L. Daley, Brian Shine, Robert Wilson and Nuala Whitehead and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Charles Haworth

125 papers receiving 4.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

2017 529 citations Charles Haworth, Michael R. Loebinger et al. profile →
Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study

2013 472 citations Josephine M. Bryant, Dorothy Grogono et al. The Lancet profile →
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary

2015 360 citations R. Andrés Floto, Charles L. Daley et al. profile →
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

2015 303 citations R. Andrés Floto, Charles L. Daley et al. profile →
Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

2020 207 citations James D. Chalmers, Charles Haworth et al. New England Journal of Medicine profile →
Future therapies for cystic fibrosis

2023 71 citations Charles Haworth et al. profile →
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

2025 26 citations James D. Chalmers, Pierre‐Régis Burgel et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Haworth United Kingdom	33	2.3k	2.3k	1.3k	967	611	134	5.0k
Lea Bentur Israel	33	2.6k 1.1×	680 0.3×	248 0.2×	105 0.1×	487 0.8×	152	3.8k
Muriel Le Bourgeois France	32	1.7k 0.7×	840 0.4×	419 0.3×	247 0.3×	440 0.7×	121	3.1k
D. B. HORN United States	34	349 0.1×	2.3k 1.0×	1.6k 1.2×	182 0.2×	1.5k 2.5×	152	4.6k
Rinaldo Pellicano Italy	37	953 0.4×	1.8k 0.8×	273 0.2×	269 0.3×	2.7k 4.5×	410	5.9k
Anders Lindblad Sweden	25	2.1k 0.9×	559 0.2×	255 0.2×	111 0.1×	375 0.6×	80	2.7k
Inderpaul Singh Sehgal India	32	2.2k 0.9×	785 0.3×	1.9k 1.4×	145 0.1×	385 0.6×	202	3.7k
Hoda M. Malaty United States	41	1.6k 0.7×	804 0.4×	298 0.2×	871 0.9×	6.4k 10.4×	112	7.4k
Allan R. Glanville Australia	44	3.5k 1.5×	1.9k 0.8×	439 0.3×	64 0.1×	5.4k 8.8×	203	8.1k
Rachel A. Carter United States	14	230 0.1×	2.3k 1.0×	2.0k 1.5×	314 0.3×	110 0.2×	15	4.1k
G. Lenoir France	31	1.3k 0.6×	548 0.2×	203 0.2×	82 0.1×	299 0.5×	126	2.8k

Countries citing papers authored by Charles Haworth

Since Specialization

Citations

This map shows the geographic impact of Charles Haworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Haworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Haworth more than expected).

Fields of papers citing papers by Charles Haworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Haworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Haworth. The network helps show where Charles Haworth may publish in the future.

Co-authorship network of co-authors of Charles Haworth

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Haworth. A scholar is included among the top collaborators of Charles Haworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Haworth. Charles Haworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chalmers, James D., Pierre‐Régis Burgel, Charles L. Daley, et al.. (2025). Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine. 392(16). 1569–1581. 26 indexed citations breakdown →

Meerburg, Jennifer J., Eleni‐Rosalina Andrinopoulou, Pierluigi Ciet, et al.. (2024). Structural Lung Disease and Clinical Phenotype in Bronchiectasis Patients: The EMBARC CT Study. American Journal of Respiratory and Critical Care Medicine. 210(1). 87–96. 8 indexed citations

Perea, Lídia, Jennifer S. Pollock, Chloe Hughes, et al.. (2024). Changes in Blood Immune Cell Transcriptomes Associate With Disease Severity, Infection, and Inflammation in Bronchiectasis Patients: Data From the EMBARC-BRIDGE Study. A1030–A1030.

Chalmers, James D., Pierre‐Régis Burgel, Charles L. Daley, et al.. (2024). Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics. ERJ Open Research. 10(4). 151–2024. 15 indexed citations

Metersky, Mark L., Pierre‐Régis Burgel, Charles L. Daley, et al.. (2024). ANNUALIZED EXACERBATION RATE IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS BY PRESPECIFIED SUBGROUPS IN THE PH3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ASPEN TRIAL. CHEST Journal. 166(4). A6554–A6556. 2 indexed citations

Meerburg, Jennifer J., Eleni‐Rosalina Andrinopoulou, Pierluigi Ciet, et al.. (2024). Automated method of bronchus and artery dimension measurement in an adult bronchiectasis population. ERJ Open Research. 10(6). 231–2024. 1 indexed citations

Loebinger, Michael R., Stefano Aliberti, Charles Haworth, et al.. (2024). Patients at risk of nontuberculous mycobacterial pulmonary disease who need testing evaluated using a modified Delphi process by European experts. ERJ Open Research. 10(5). 791–2023. 1 indexed citations

Chalmers, James D., Michael R. Loebinger, Ariel Teper, et al.. (2024). Brensocatib in patients with bronchiectasis: subgroup analyses from the WILLOW trial. ERJ Open Research. 11(1). 505–2024. 3 indexed citations

Pollock, Jennifer S., Eva Polverino, Charles Haworth, et al.. (2023). S146 Aspergillus in bronchiectasis: data from the EMBARC registry. A106–A106.

10.

Elborn, J.S., Francesco Blasi, Charles Haworth, et al.. (2022). Bronchiectasis and inhaled tobramycin: A literature review. Respiratory Medicine. 192. 106728–106728. 21 indexed citations

11.

Schildkraut, Jodie A., Jack R. Gallagher, Kozo Morimoto, et al.. (2020). Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respiratory Medicine. 173. 106164–106164. 28 indexed citations

12.

Loebinger, Michael R., Eva Polverino, Francesco Blasi, et al.. (2019). Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). Pulmonary Pharmacology & Therapeutics. 58. 101834–101834. 7 indexed citations

13.

Moore, Matthew, Iain L. Lamont, Diana Bilton, et al.. (2017). Pseudomonas aeruginosaadaptation and diversification in the non-cystic fibrosis bronchiectasis lung. European Respiratory Journal. 49(4). 1602108–1602108. 68 indexed citations

14.

Haworth, Charles, et al.. (2014). Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection. American Journal of Respiratory and Critical Care Medicine. 189(8). 975–982. 185 indexed citations

15.

Wagner, Dirk, Jakko van Ingen, Jennifer Adjemian, et al.. (2014). Annual prevalence and treatment estimates of nontuberculous mycobacterial pulmonary disease in Europe: A NTM-NET collaborative study. European Respiratory Journal. 44(Suppl 58). P1067–P1067. 10 indexed citations

16.

Ingen, Jakko van, Jennifer Adjemian, Kozo Morimoto, et al.. (2014). Comparison of treatment practices for nontuberculous mycobacterial pulmonary disease in Japan, Europe, and United States. European Respiratory Journal. 44(Suppl 58). P1066–P1066. 2 indexed citations

17.

Bryant, Josephine M., Dorothy Grogono, Daniel Greaves, et al.. (2013). Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. The Lancet. 381(9877). 1551–1560. 472 indexed citations breakdown →

18.

Barker, Helen, et al.. (2011). 368* Aetiology of erectile dysfunction in cystic fibrosis. Journal of Cystic Fibrosis. 10. S94–S94. 2 indexed citations

19.

Haworth, Charles, et al.. (2006). Osteoclastogenesis during Infective Exacerbations in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 174(3). 306–311. 44 indexed citations

20.

Verma, Arpana, M Dodd, Charles Haworth, & A.K. Webb. (2000). Holidays and cystic fibrosis.. Europe PMC (PubMed Central). 93 Suppl 38. 20–6. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact